ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 275

Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab

Tomohiro Kubota1, Syuji Takei2, Yuichi Yamasaki1, Junko Yasumura3, Naomi Kuwada4, Yukiko Nonaka5, Tomoko Takezaki5, Tsuyoshi Yamatou5, Tomokazu Nagakura6, Yasuhito Nerome5, Hiroyuki Imanaka5 and Harumi Akaike5, 1Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 2School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 3Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, 4Dept of Pediatrics, Faculuty of Medicine, Kumamoto University, Kumamoto City, Japan, 5Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, 6Department of Pediatrics, House of Meguminoseibo, Usuki, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IL-1/IL-18, remission and tocilizumab, Systemic JIA

  • Tweet
  • Email
  • Print
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan. We have previously reported that long-term TCZ therapy could induce drug-free remission in sJIA patients resistant to conventional prednisolone (PSL) therapy1). On the other hand, extremely high levels of serum IL-18 (>10,000 pg/ml) was reported in active phase of sJIA2). Therefore, serum IL-18 levels were monitored in order to find the way how to taper and discontinue TCZ in sJIA patients.

Methods: sJIA patients treated with 8 mg/kg of TCZ for more than 1 year who were initially resistant to 3 times of consecutive weekly methyl-PSL pulse therapy in active phase and/or had been refractory to long-term oral steroid therapy were recruited. Our tapering protocol for patients who maintained clinical remission by TCZ was as following; decrease PSL dose gradually to less than 0.2mg/kg/day, prolongation of TCZ interval from every 2w to 3w, discontinuation of PSL, and discontinuation of TCZ, in tern.  Serum levels of IL-6/IL-18 were measured by ELISA .

Results: A total of 28 sJIA patients were recruited in this study; their mean disease duration was 4.1 years, and mean PSL dose was 0.5mg/kg/day at initiating TCZ.

Twenty-seven patients (96%) attained clinical remission with combination therapy of PSL<0.2mg/kg/day and TCZ every 3w. Thereafter, 10 patients (36%) completed PSL-free remission, and 7 (25%) attained drug-free remission by discontinued TCZ (Figure 1). No significant difference was found in TCZ treatment period between the two patient groups who achieved the drug-free remission (mean 7.0 yrs) and who maintained clinical remission (mean 5.5 yrs).

Serum IL-6 decreased quickly in correlating with improvement of clinical symptoms after starting TCZ. On the contrary, serum IL-18 did not decrease in a patient who was resistant to TCZ therapy, or in patients who flared or developed to macrophage activation syndrome during the TCZ therapy.  In patients who attained clinical remission by TCZ, however, IL-18 steadily decreased with treatment course (figure 2).  In all patients maintained the drug-free remission for more than 2 years, serum IL-18 was < 1,000 pg/ml when the TCZ was discontinued.

Conclusion: TCZ had the potential to induce drug-free remission in 1/4 of sJIA patients who had been refractory to the conventional therapy.  Serum IL-18 level could be a useful bio-marker in tapering the TCZ therapy in sJIA.

1) Kubota T, et al: #267, 2011 ACR meeting

2) Shimizu M, et al�FRheumatology 2010;49:1645-1653


Disclosure:

T. Kubota,
None;

S. Takei,

Chugai,Eisai, Takeda, Bristol-Myers,

2,

Caugai, Eisai, Takeda, Abbvie, Astellas, Teijin, Novartis, Pfizer, Asahi Kasei,

8;

Y. Yamasaki,
None;

J. Yasumura,
None;

N. Kuwada,
None;

Y. Nonaka,
None;

T. Takezaki,
None;

T. Yamatou,
None;

T. Nagakura,
None;

Y. Nerome,
None;

H. Imanaka,
None;

H. Akaike,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-serum-il-18-level-in-systemic-juvenile-idiopathic-arthritis-patients-who-attained-drug-free-remission-by-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies